Cannabis Chart Of The Week: Consensus 2024 EBITDA Estimates Are Still Up 8.4% Despite Downward Revisions
Cannabis Chart Of The Week: Consensus 2024 EBITDA Estimates Are Still Up 8.4% Despite Downward Revisions
大麻股本週圖表：儘管經常性EBITDA預估有所下調，但2024年的共識仍然增長了8.4%。
The chart shows the percentage change in consensus 2024 EBITDA estimates between the end of 2023 and now. The orange bars represent the portion of EBITDA % change attributable to changes in EBITDA Margins, while the blue bars depict the part attributable to changes in revenue estimates.
本圖顯示了2024年EIBTDA預測的一致性變化百分比，從2023年底到現在。橙色柱代表EIBTDA%變化中歸因於EIBTDA利潤率變化的部分，而藍色柱代表歸因於營業收入預測變化的部分。
In aggregate, the group 2024 EBITDA estimates have been revised downward by 4.5% YTD, and 2.7% of that has occurred since the end of the second quarter. The range is quite wide, however, from a 48.3% downward revision for MariMed (OTC:MRMD) to an upward revision of 23.9% for Trulieve (OTC:TCNNF).
總體上，2024年EIBTDA預測已經從今年初下調了4.5％，其中有2.7％發生在第二季度末之後。然而，這一範圍相當廣泛，從MariMed（場外交易：MRMD）的下調48.3％到Trulieve（場外交易：TCNNF）上調23.9％。
We had expected 2024 revisions to be going in the...
我們原本預期202...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間